Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Trends in Endocrinology   Volumes    Volume 7 
Discontinuation of dopamine agonists after treatment of prolactinoma
Bernard Corenblum
Pages: 95 - 98
Number of pages: 4
Current Trends in Endocrinology
Volume 7 

Copyright © 2014 Research Trends. All rights reserved

After years of successful therapy for pathological hyperprolactinemia with dopamine agonists, an attempt of drug withdrawal could be undertaken in selected clinically stable patients. Either long-term remission or relapse of disease may occur. Disease relapse should be defined as hyperprolactinemia with return of clinical symptoms, not just the biochemical marker itself. With this definition in 168 patients, 37% of the bromocriptine group and 22% of the cabergoline group did have a biochemical and clinical relapse and were re-administered the dopamine agonist. The remainder were clinically asymptomatic, despite return of hyperprolactinemia in some, but they did not require further therapy. An asymptomatic increase of serum prolactin does not change the clinical state of remission.
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms